CoreWeave vs Neurocrine Biosciences Inc — how do they compare? CoreWeave trades at $83.4 (market cap $44.99B), while Neurocrine Biosciences Inc trades at $141.09 (market cap $14.36B). The key difference: CoreWeave is far larger — about 3.1× Neurocrine Biosciences Inc's market cap, and CoreWeave is more actively traded (41,993,776 versus 1,237,180). Which is the better fit depends on your goals — on Pluang, investors hold CoreWeave for 6 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CRWV | NBIX | |
|---|---|---|
Market Cap | $44.99B | $14.36B |
Volume | 41,993,776 | 1,237,180 |
Sector | Technology | Health |
52-Week High | $143.08 | $185.50 |
52-Week Low | $60.82 | $123.10 |
Typical Hold Time | 6 Days | 23 Days |
Enterprise Value | $91.06B | $14.37B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, amid a bearish technical signal. The stock shows strong fundamentals with a 20.91% net income margin and consistent earnings beats, including a Q2 2026 EPS of $2.85 versus $1.85 expected. Recent news highlights pipeline advancements in Prader-Willi syndrome and active participation in investor conferences. Key support is at $142, with resistance at $145.
The outlook is positive, driven by robust product growth, particularly from Ingrezza and Crenessity, and a deep pipeline. Risks include pricing pressures on Ingrezza by 2029 and execution challenges in portfolio expansion. Analyst consensus is strongly bullish with a $204.18 price target, suggesting significant upside from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CoreWeave provides cloud computing infrastructure designed for AI workloads. Its platform gives organizations access to large-scale GPU computing and cloud services for training and running AI models.
Read more on CRWV →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →